Standard BioTools Q1 adjusted EBITDA loss narrows

Standard BioTools

05/05/2026 21:41

Overview

U.S. life science tools firm's Q1 revenue rose 5% yr/yr, driven by consumables growth

Q1 adjusted EBITDA loss narrowed and beat analyst expectations, aided by cost savings

Instrument revenue fell 33% yr/yr due to capital-constrained end-markets

Outlook

Standard BioTools expects 2026 revenue in the range of $80 mln to $85 mln

Company says cost savings initiatives support path to positive adjusted EBITDA exiting 2026

Standard BioTools says strong balance sheet provides flexibility for strategic capital deployment

Result Drivers

CONSUMABLES GROWTH - Q1 consumables revenue rose 35% yr/yr, driven by growth across all product categories, primarily microfluidics

INSTRUMENT WEAKNESS - Instrument revenue fell 33% yr/yr, impacted by capital-constrained end-markets and a strong prior-year comparison

COST REDUCTIONS - Operating expenses fell 37% yr/yr, largely due to previously announced restructuring actions

Company press release: ID:nGNXbLNcBN

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$21.10 mln
Q1 EPS
$0.33
Q1 Net Income
$127.07 mln
Q1 Adjusted EBITDA
Beat
-$3.10 mln
-$9.77 mln (3 Analysts)
Q1 Gross Margin
53.50%
Q1 Adjusted Gross Margin
57.70%
Q1 Operating Income
-$12.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Standard BioTools Inc is $1.55, about 65.8% above its May 4 closing price of $0.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)